New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide

被引：0

作者：

Sakae Tanaka ^{[1
]}

Taiji Adachi ^{[2
]}

Tatsuhiko Kuroda ^{[3
]}

Toshitaka Nakamura ^{[4
]}

Masataka Shiraki ^{[5
]}

Toshitsugu Sugimoto ^{[6
]}

Yasuhiro Takeuchi ^{[7
]}

Mitsuru Saito ^{[8
]}

John P Bilezikian ^{[9
]}

机构：

[1] Department of Orthopaedic Surgery,Faculty of Medicine,University of Tokyo,Tokyo,Japan

[2] Department of Biomechanics,Institute for Frontier Medical Sciences,Kyoto University,Kyoto,Japan

[3] Medical Affairs Department,Asahi Kasei Pharma Corporation,Tokyo,Japan

[4] National Center for Global Health and Medicine,Tokyo,Japan

[5] Research Institute and Practice for Involutional Diseases,Nagano,Japan

[6] Internal Medicine ,Shimane University Faculty of Medicine,Izumo,Japan

[7] Toranomon Hospital Endocrine Center,Tokyo,Japan

[8] Department of Orthopaedic Surgery,Jikei University School of Medicine,Tokyo,Japan

[9] Metabolic Bone Diseases Program,Division of Endocrinology,Department of Medicine,College of Physicians and Surgeons,Columbia University,New York,USA

来源：

Bone Research | 2014年 / 2卷 / 04期

关键词：

bone; New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide; BMD;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

1002 ; 100201 ;

摘要：

Daily 20-mg and once-weekly 56.5-mg teriparatide(parathyroid hormone 1–34) treatment regimens increase bone mineral density(BMD) and prevent fractures, but changes in bone turnover markers differ between the two regimens. The aim of the present study was to explain changes in bone turnover markers using once-weekly teriparatide with a simulation model. Temporary increases in bone formation markers and subsequent decreases were observed during once-weekly teriparatide treatment for 72 weeks. These observations support the hypothesis that repeated weekly teriparatide administration stimulates bone remodeling, replacing old bone with new bone and leading to a reduction in the active remodeling surface. A simulation model was developed based on the iterative remodeling cycle that occurs on residual old bone. An increase in bone formation and a subsequent decrease were observed in the preliminary simulation. For each fitted time point, the predicted value was compared to the absolute values of the bone formation and resorption markers and lumbar BMD. The simulation model strongly matched actual changes in bone turnover markers and BMD. This simulation model indicates increased bone formation marker levels in the early stage and a subsequent decrease. It is therefore concluded that remodeling-based bone formation persisted during the entire treatment period with once-weekly teriparatide.

引用

页码：252 / 258

页数：7

共 11 条

[1]

Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide[J] . Shiro Tanaka,Tatsuhiko Kuroda,Toshitsugu Sugimoto,Toshitaka Nakamura,Masataka Shiraki.Current Medical Research ＆ Opinion . 2014 (5)

[2] Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis [J].

Sugimoto, T. ;

Nakamura, T. ;

Nakamura, Y. ;

Isogai, Y. ;

Shiraki, M. .

OSTEOPOROSIS INTERNATIONAL, 2014, 25 (03) :1173-1180

[3] Osteocyte-Driven Bone Remodeling [J].

Bellido, Teresita .

CALCIFIED TISSUE INTERNATIONAL, 2014, 94 (01) :25-34

[4] Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women [J].

Shiraki, M. ;

Sugimoto, T. ;

Nakamura, T. .

OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) :219-226

[5]

Randomized Teriparatide[Human Parathyroid Hormone （PTH） 1–34] Once-Weekly Efficacy Research （TOWER） Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk[J] . Toshitaka Nakamura,Toshitsugu Sugimoto,Tetsuo Nakano,Hideaki Kishimoto,Masako Ito,Masao Fukunaga,Hiroshi Hagino,Teruki Sone,Hideki Yoshikawa,Yoshiki Nishizawa,Takuo Fujita,Masataka Shiraki.The Journal of Clinical Endocrinology ＆ Metabolism . 2012 (9)

[6]

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once‐yearly zoledronic acid 5 mg: The HORIZON‐Pivotal Fracture Trial （PFT）[J] . Richard M Jacques,Steven Boonen,Felicia Cosman,Ian R Reid,Douglas C Bauer,Dennis M Black,Richard Eastell.J Bone Miner Res . 2012 (8)

[7]

Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases[J] . Akimitsu Miyauchi,Toshio Matsumoto,Toshitsugu Sugimoto,Mika Tsujimoto,Margaret R. Warner,Toshitaka Nakamura.Bone . 2010 (3)

[8] Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment [J].